A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results
#1179
Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Aim(s): To evaluate the safety and efficacy of axitinib in patients with advanced carcinoid tumors
Materials and methods: We performed a phase II trial of axitinib 5 mg BID in patients with advanced low to intermediate grade carcinoid tumors. Prior antiangiogenic therapy with a dedicated VEGF pathway inhibitor was not permitted. The primary endpoints were PFS and 1-year PFS rate
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Cives M, Strosberg J, Campos T, Weber T, Nickerson M,
Keywords: axitinib, anti-angiogenesis, VEGFR,
To read the full abstract, please log into your ENETS Member account.